[Pharmacokinetic studies of 5-nitrox in kidney failure patients].
The authors carried out initial pharmacokinetic studies of 5-nitrox on patients with compensated, first and second degree of decompensated renal insufficiency in view of determining dosage and intervals for application of the preparation. They found regular changes in the profile of the curves, manifesting the concentrations of 5-nitrox in plasma and urine for each interval of time-with advancement of renal insufficiency the peak levels diminished and were seen at later intervals as the course of the curves were of plateau character in patients with second degree of renal insufficiency. The analysis of the results showed that treatment of patients with decompensated renal insufficiency was not justified due to the retention of relatively high plasma level up to the 12th hour and rather low, unefficient concentrations of urine. 5-nitrox could be used in a single dose of 200 mg at 8-hour intervals in patients with compensated first degree of decompensated renal insufficiency.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009600:Nitroquinolines / Q000008:administration & dosage / Q000378:metabolism*; D013997:Time Factors
D009600:Nitroquinolines; C005308:nitroxoline
Niakoi farmakokinetichni prouchvaniia na 5-nitroks pri bolni s bŭbrechna nedostatŭchnost.